FDA Panel Narrowly Backs GRAIL's Galleri, the First Multi-Cancer Blood Test to Reach an Advisory Vote

Advisers split 6-4 on whether the screening test is effective while voting 10-0 that it is safe, leaving the agency a contested record to weigh.

By Marcus Elrod

Sep 25, 2026 · 7 min read

A Food and Drug Administration advisory panel voted narrowly on Sept. 23 that GRAIL's Galleri test is effective, the first time a multi-cancer early detection blood test has reached an advisory committee vote in the United States.

Discussion (0)

Loading comments…

Marcus Elrod

Marcus tracks positioning, flows and rates. He writes CI's weekly market internals column.

Marcus Elrod writes for Corporate Insider Inc.

CII Briefing

The 7am memo for people who run things

One email. The deals, the numbers and the decisions that will be discussed in your Monday meeting.